PMPedro Madureira

Pedro Madureira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Madureira has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Manuel Vilanova

    Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal

    13 shared publications
  • Nuno Filipe Azevedo

    LEPABE/ALiCE-Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

    8 shared publications
  • Paula Ferreira

    Affiliations: ICBAS, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal

    8 shared publications
  • Manuel António Coimbra

    LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal

    6 shared publications
  • Adília Ribeiro

    I3S—Instituto de Investigação e Inovação em Saúde/IBMC—Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal

    5 shared publications
  • Jesper Wengel

    Biomolecular Nanoscale Engineering Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark

    5 shared publications

Latest Publications

  • Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia

    by Marta Lopes, Filipa Lemos, Lídia Rocha, Carolina Pereira, Catarina Moreira-Barbosa, Joana P. Reis, Tiago L. Duarte, André M. N. Silva, Nuno Gonçalves, Laura Mosteo, et al.

    Acute myeloid leukemia (AML) is an aggressive leukemia with high rates of chemoresistance and relapse. Patients with AML undergoing induction chemotherapy often have delayed erythropoietic recovery and febrile neutropenia. Infection is a leading cause of mortality in this population. There is an unmet need to improve disease-specific outcomes in patients with AML undergoing cytotoxic chemotherapy. AML, at diagnosis, is characterized by increased levels of circulating iron due to erythroid block and cell death, which is further aggravated upon intensive chemotherapy. We hypothesized that iron, particularly toxic non–transferrin-bound iron (NTBI), can be redistributed away from AML cells and bacteria into nonmalignant transferrin receptor (CD71)–expressing cells by administering exogenous iron-free apotransferrin (apoTF). Using mouse models of AML, we show that mice treated with human apoTF had decreased NTBI and increased bone marrow erythropoiesis and B cell responses. ApoTF treatment resulted in normalization of bone marrow blood vessels and reduction of lipid peroxidation in endothelial cells. Crucially, apoTF combined with chemotherapy resulted in a reduction of AML cells and in improved survival, which was dependent on adaptive immunity. We established a murine model of Escherichia coli sepsis in leukemic mice receiving chemotherapy. We show that apoTF administration increased the survival of E. coli –infected mice. Mechanistically, apoTF treatment decreased the levels of circulating C-C motif chemokine ligand 2 (CCL2) and interleukin-6 through reduced expression of CCL2 in lipopolysaccharide-polarized macrophages. Our results demonstrate an overall benefit of iron redistribution induced by transferrin in combination with cytotoxic chemotherapy in AML.

  • Open Access

    Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae or Streptococcus agalactiae

    by Carolina Fernandes, Filipa Lemos, Liliana Curado, Bruno L. Victor, Maelenn Chevreuil, Inês Machado, Sofia Teixeira, Maria Do Carmo Koch, Marta Vieira, Patrick England, et al.

    Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a highly conserved bacterial enzyme essential for glycolysis, yet it also plays important non-metabolic, “moonlighting” roles, including host immunomodulation. Here, we describe the generation and characterization of a monoclonal antibody (mAb01) that targets extracellular GAPDH from Streptococcus agalactiae (GBS) and Streptococcus pneumoniae . Using bio-layer interferometry (BLI) and surface plasmon resonance (SPR), we demonstrate that mAb01 binds with high affinity, exhibiting dissociation constants in the low nanomolar range for both antigens. Functionally, mAb01 significantly improves survival in a neonatal murine model of sepsis caused by either GBS or S. pneumoniae , two relevant neonatal pathogens. The addition of mAb01 to ex vivo cultures of human peripheral blood infected with GBS or S. pneumoniae induced a significant decrease in bacterial replication, further supporting its protective potential. These results provide the first demonstration of a high-affinity anti-GAPDH monoclonal antibody that is effective in both in vivo and ex vivo models of streptococcal infection.

  • Open Access

    Low levels of circulating IgG against bacterial GAPDH and elevated IL-10 levels are associated with increased susceptibility to Escherichia coli bacteraemia

    by Ana Fidalgo, Filipa Lemos, Joana B. Nunes, Carla Teixeira, Cristiana Nogueira, Hugo Osório, Sofia Botelho Moniz, Cristina Martins Silva, Carolina Lemos, Pedro Castanheira, et al.

    Background: While antimicrobial resistance is an increasingly urgent problem, with Escherichia coli infections representing a major priority, the development of effective vaccines has proven both challenging and largely unsuccessful. Given accumulating evidence supporting the immunosuppressive role of extracellular bacterial glyceraldehyde-3-phosphate dehydrogenase (GAPDH), we aimed to characterize individual susceptibility to E. coli infections based on the presence of naturally induced antibodies against this protein. Methods: We conducted an observational case-control study including 62 individuals with E. coli bacteraemia (cases) and 124 age- and sex-matched controls without infection. Detection of GAPDH was performed in plasma samples, and plasma interleukin (IL)-10 levels and anti-GAPDH IgG (titers and concentrations) were quantified. Associations between anti-GAPDH IgG levels and infection were evaluated using logistic regression, and individual disease risk was estimated with a multivariate model incorporating IL-10 detection and low levels of anti-GAPDH IgG. Results: E. coli GAPDH was detected in the plasma of cases from which purified colonies of E. coli were isolated. IL-10 levels were significantly higher (p < 0.0001) in cases while anti-GAPDH IgG levels were significantly lower (p < 0.0001) comparing with controls. Logistic regression analysis revealed a strong inverse association between anti-GAPDH IgG and the diagnosis of E. coli bacteraemia (adjusted OR = 0.18, 95% CI 0.08-0.37) and a protective threshold of 1.0 μg/mL was estimated, below which, 95.2% of cases were classified. In a multivariate logistic regression model, detection of IL-10 was strongly associated with infection risk (OR = 629, 95% CI 139–5355), while low anti-GAPDH IgG showed a trend towards increased risk (OR = 4.26, 95% CI 0.91–30.6). This model allowed the estimation of individual probabilities and absolute risk of E. coli bacteraemia using a combining biomarker based on levels of anti-GAPDH IgG and IL-10. Conclusions: This study provides the first evidence in humans of the protective potential of circulating anti-GAPDH antibodies, which supports GAPDH as a promising target for an alternative vaccination strategy to prevent E. coli infections.

  • Open Access

    Maternal transfer of anti-GAPDH IgG prevents neonatal infections caused by Staphylococcus aureus and group B Streptococcus

    by Filipa Lemos, Marta Vieira, Ana Fidalgo, Liliana Curado, Cristiana Nogueira, Joana B. Nunes, Joana Mafra, Cátia Silva, Olga Caramelo, Maria Do Céu Almeida, et al.


  • Immune aging in diabetes and its implications in wound healing

    by J. Moura, P. Madureira, E.C. Leal, A.C. Fonseca, E. Carvalho


  • Structural polymeric features that contribute to in vitro immunostimulatory activity of instant coffee

    by Sónia S. Ferreira, Cláudia P. Passos, Márcio R. Cepeda, Guido R. Lopes, Maria Teixeira-Coelho, Pedro Madureira, Fernando M. Nunes, Manuel Vilanova, Manuel A. Coimbra


  • Open Access

    Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis

    by Ramon Andrade De Mello, Carles Escriu, Pedro Castelo-Branco, Paloma Lucena Cabral, Giannis Mountzios, Gilberto de Lima Lopes, Pedro Madureira

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ramon Andrade De Mello1, 2, 3, Carles Escriu4, 5, Pedro Castelo-Branco1, 2, 5, Paloma Lucena Cabral7, Giannis Mountzios8, Gilberto de Lima Lopes9 and Pedro Madureira10 1Division of Oncology, School of Medicine, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal 2Algarve Biomedical Center, Campus Gambelas, Faro, Portugal 3Research Centre/Department of Medical Oncology, Haroldo Juaçaba Hospital, Ceará Cancer Institute, Fortaleza, CE, Brazil 4Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Warrington, Wirral and Liverpool, Merseyside, United Kingdom 5Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, The University of Liverpool, Liverpool, United Kingdom 6Centre for Biomedical Research, University of Algarve, Faro, Portugal 7Special Training Program (PET), Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil 8Department of Medical Oncology, University of Atheens, Atheens, Greece 9Sylvester Comprehensive Cancer Centre at the University of Miami, Miami, FL, USA 10Institute for Molecular and Cell Biology (IBMC) and Health Institute for Research and Innovation (i3S), University of Porto, Porto, Portugal Correspondence to: Ramon Andrade De Mello, email: ramondemello@gmail.com Keywords: non-small cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitors Received: June 20, 2017 Accepted: October 30, 2017 Published: December 23, 2017 ABSTRACT Introduction: Tyrosine kinase inhibition of the epidermal growth factor receptor (EGFR) is the standard in the first line treatment of patients with advanced non-small–cell lung cancer (NSCLC) harbouring EGFR activating mutations. Here we aim to discern efficacy and toxicity measures through a meta-analysis of published studies that could aid treatment selection. Materials And Methods: We performed a meta-analysis of the main randomized clinical trials evaluating the currently approved EGFR-TKIs in first-line of treatment of EGFR-positive advanced NSCLC. Cochrane guidelines were used for statistical analysis. Results: 3,179 patients were included. All EGFR TKIs showed improved outcomes with respect to ORR and PFS when compared to standard platinum-doublet chemotherapy. Comparative ORR for gefitinib, erlotinib and afatinib were 52.1%, 67.3% and 61.6% respectively. HRs for PFS were 0.62 (95% CI, 0.38–1.00) for gefitinib, 0.28 (95% CI, 0.17–0.45) for erlotinib and 0.40 (95% CI, 0.20–0.83) for afatinib. HRs for OS were not statistically significant for any agent. Conclusions: Our results suggest similar clinical efficacy and higher toxicity of Afatinib treatment. As this still remains the agent with best CSF penetration, we suggest its use is limited to patients presenting with brain metastasis. We suggest the use of Gefitinib in patients without CNS involvement. Faced with the impossibility to dose-reduce Gefitinib, Erlotinib represents a tolerable and effective alternative to Afatinib and Gefitinib if response to EGFR inhibition is considered still effective.


  • FISHji: New ImageJ macros for the quantification of fluorescence in epifluorescence images

    by Sílvia Fontenete, Daniel Carvalho, Anália Lourenço, Nuno Guimarães, Pedro Madureira, Céu Figueiredo, Nuno Filipe Azevedo